Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China

被引:24
作者
Du, Ruofei [1 ,2 ,3 ]
Wang, Xin [1 ]
Ma, Lixia [4 ]
Larcher, Leon M. [5 ]
Tang, Han [1 ]
Zhou, Huiyue [1 ]
Chen, Changying [2 ]
Wang, Tao [1 ,5 ,6 ]
机构
[1] Zhengzhou Univ, Coll Nursing & Hlth, Zhengzhou 450001, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China
[3] Zhengzhou Univ, Sch Med Sci, Zhengzhou 450001, Peoples R China
[4] Henan Univ Econ & Law, Sch Stat, Zhengzhou 450046, Peoples R China
[5] Murdoch Univ, Ctr Comparat Genom, Perth, WA 6150, Australia
[6] Hebi Peoples Hosp, Hebi 458030, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
Adverse reactions; Cancer patients; Hospitalization; Targeted therapy; Quality of life; EFFICACY; EVENTS; IMPACT; EGFR;
D O I
10.1186/s12885-021-07946-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The adverse reactions (ADRs) of targeted therapy were closely associated with treatment response, clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation between ADRs of targeted therapy and treatment effects among cancer patients. This study was to explore the characteristics of ADRs with targeted therapy and the prognosis of cancer patients based on the clinical data. Methods A retrospective secondary data analysis was conducted within an ADR data set including 2703 patients with targeted therapy from three Henan medical centers of China between January 2018 and December 2019. The significance was evaluated with chi-square test between groups with or without ADRs. Univariate and multivariate logistic regression with backward stepwise method were applied to assess the difference of pathological characteristics in patients with cancer. Using the univariate Cox regression method, the actuarial probability of overall survival was performed to compare the clinical outcomes between these two groups. Results A total of 485 patients were enrolled in this study. Of all patients, 61.0% (n = 296) occurred ADRs including skin damage, fatigue, mucosal damage, hypertension and gastrointestinal discomfort as the top 5 complications during the target therapy. And 62.1% of ADRs were mild to moderate, more than half of the ADRs occurred within one month, 68.6% ADRs lasted more than one month. Older patients (P = 0.022) and patients with lower education level (P = 0.036), more than 2 comorbidities (P = 0.021), longer medication time (P = 0.022), drug combination (P = 0.033) and intravenous administration (P = 0.019) were more likely to have ADRs. Those with ADRs were more likely to stop taking (P = 0.000), change (P = 0.000), adjust (P = 0.000), or not take the medicine on time (P = 0.000). The number of patients with recurrence (P = 0.000) and metastasis (P = 0.006) were statistically significant difference between ADRs and non-ADRs group. And the patients were significantly poor prognosis in ADRs groups compared with non-ADRs group. Conclusion The high incidence of ADRs would affect the treatment and prognosis of patients with cancer. We should pay more attention to these ADRs and develop effective management strategies.
引用
收藏
页数:13
相关论文
共 36 条
  • [1] Armstrong Terri S, 2003, Oncol Nurs Forum, V30, P601, DOI 10.1188/03.ONF.601-606
  • [2] Efficacy, safety, tolerability and price of newly approved drugs in solid tumors
    Barnes, Tristan A.
    Amir, Eitan
    Templeton, Arnoud J.
    Gomez-Garcia, Susana
    Navarro, Beatriz
    Seruga, Bostjan
    Ocana, Alberto
    [J]. CANCER TREATMENT REVIEWS, 2017, 56 : 1 - 7
  • [3] Dernnatologic Reactions to Targeted Therapy A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care
    Barton-Burke, Margaret
    Ciccolini, Kathryn
    Mekas, Maria
    Burke, Sean
    [J]. NURSING CLINICS OF NORTH AMERICA, 2017, 52 (01) : 83 - +
  • [4] Kinase-targeted cancer therapies: progress, challenges and future directions
    Bhullar, Khushwant S.
    Orrego Lagaron, Naiara
    McGowan, Eileen M.
    Parmar, Indu
    Jha, Amitabh
    Hubbard, Basil P.
    Rupasinghe, H. P. Vasantha
    [J]. MOLECULAR CANCER, 2018, 17
  • [5] The Medical Dictionary for Regulatory Activities (MedDRA)
    Brown, EG
    Wood, L
    Wood, S
    [J]. DRUG SAFETY, 1999, 20 (02) : 109 - 117
  • [6] Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib's Toxicities in Hepatocellular Carcinoma
    Brunot, Angelique
    Le Roy, Florence
    Le Sourd, Samuel
    M'Sadek, Amel
    Duval, Marielle
    Crouzet, Laurence
    Guillygomarc'h, Anne
    Boucher, Eveline
    Laguerre, Brigitte
    Edeline, Julien
    [J]. CANCER NURSING, 2018, 41 (05) : 418 - 423
  • [7] Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
    Cazzaniga, Marina Elena
    Danesi, Romano
    Girmenia, Corrado
    Invernizzi, Pietro
    Elvevi, Alessandra
    Uguccioni, Massimo
    Gila, Monica Perez
    Amaducci, Laura
    Atzori, Francesco
    Blasi, Livio
    Butti, Chiara
    Collova, Elena
    De Conciliis, Enrico
    Fabi, Alessandra
    Febbraro, Antonio
    Garrone, Ornella
    Gianni, Lorenzo
    Giotta, Francesco
    La Verde, Nicla
    Michelotti, Andrea
    Palumbo, Raffaella
    Paris, Ida
    Pistelli, Mirco
    Pizzuti, Laura
    Rubino, Daniela
    Valerio, Maria Rosaria
    Zustovich, Fable
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 483 - 494
  • [8] A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy
    Chan, Jui-Chun
    Lee, Yun-Hsiang
    Liu, Chien-Ying
    Shih, Hui-Hsuan
    Tsay, Pei-Kwei
    Tang, Woung-Ru
    [J]. JOURNAL OF NURSING RESEARCH, 2019, 27 (06)
  • [9] Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study
    Chan, Sze Ling
    Ang, Xiaohui
    Sani, Levana L.
    Ng, Hong Yen
    Winther, Michael D.
    Liu, Jian Jun
    Brunham, Liam R.
    Chan, Alexandre
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (06) : 1636 - 1646
  • [10] Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
    Chen, Chun-Bing
    Wu, Ming-Ying
    Ng, Chau Yee
    Lu, Chun-Wei
    Wu, Jennifer
    Kao, Pei-Han
    Yang, Chan-Keng
    Peng, Meng-Ting
    Huang, Chen-Yang
    Chang, Wen-Cheng
    Hui, Rosaline Chung-Yee
    Yang, Chih-Hsun
    Yang, Shun-Fa
    Chung, Wen-Hung
    Su, Shih-Chi
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1259 - 1273